| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4562424
Max Phase: Preclinical
Molecular Formula: C26H26ClN5O2
Molecular Weight: 475.98
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: CC1(C)CN(c2ccc(-c3ccc(-c4nc5cc(Cl)ccc5[nH]4)cn3)cn2)CCC1CC(=O)O
Standard InChI: InChI=1S/C26H26ClN5O2/c1-26(2)15-32(10-9-18(26)11-24(33)34)23-8-4-16(13-29-23)20-6-3-17(14-28-20)25-30-21-7-5-19(27)12-22(21)31-25/h3-8,12-14,18H,9-11,15H2,1-2H3,(H,30,31)(H,33,34)
Standard InChI Key: ZXUGLMXHJHUDQV-UHFFFAOYSA-N
Associated Targets(Human)
Diacylglycerol O-acyltransferase 1 1719 Activities
Acyl coenzyme A:cholesterol acyltransferase 1 857 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
HERG 29587 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Associated Targets(non-human)
Diacylglycerol O-acyltransferase 1 342 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Mus musculus 284745 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 475.98 | Molecular Weight (Monoisotopic): 475.1775 | AlogP: 5.67 | #Rotatable Bonds: 5 |
| Polar Surface Area: 95.00 | Molecular Species: ACID | HBA: 5 | HBD: 2 |
| #RO5 Violations: 1 | HBA (Lipinski): 7 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 1 |
| CX Acidic pKa: 4.43 | CX Basic pKa: 6.54 | CX LogP: 3.50 | CX LogD: 2.74 |
| Aromatic Rings: 4 | Heavy Atoms: 34 | QED Weighted: 0.39 | Np Likeness Score: -1.01 |
References
| 1. Yu Y, Wu Z, Shi ZC, He S, Lai Z, Cernak TA, Vachal P, Liu M, Liu J, Hong Q, Jian T, Guiadeen D, Krikorian A, Sperbeck DM, Verras A, Sonatore LM, Murphy BA, Wiltsie J, Chung CC, Gorski JN, Liu J, Xiao J, Wolff M, Tong SX, Madeira M, Karanam BV, Shen DM, Balkovec JM, De Vita RJ, Pinto S, Nargund RP.. (2019) Accelerating the discovery of DGAT1 inhibitors through the application of parallel medicinal chemistry (PMC)., 29 (11): [PMID:30952592] [10.1016/j.bmcl.2019.03.039] |
Source
Source(1):